Category
6 articles
Weight loss is the headline, but GLP-1 receptor agonists interact with organs throughout the body. We review the documented benefits, the recognised risks and the MHRA warnings every UK patient should understand before starting treatment.
Millions of UK workers hold private medical insurance or workplace health schemes without realising what they cover. This guide explains how to interrogate your policy documents, approach your employer, and make the case for funding prescription weight-loss treatment.
When GLP-1 medication shrinks your appetite, every bite has to work harder. UK-registered dietitians explain why protein targets, portion strategy and nutrient density matter more than ever when you are eating considerably less.
Being turned down for GLP-1 medication at the GP surgery can feel like a door slamming shut, but the refusal usually has a specific, explainable reason. This guide unpacks the criteria behind the 'no' and maps out the legitimate routes still open to you.
Three injectable medications dominate the UK's medical weight-loss landscape, yet they differ considerably in how they work, what they cost and who they suit. This guide sets out the key differences so patients can approach a prescriber with informed questions.
Wegovy and Mounjaro can be prescribed in Britain through two very different systems — NHS specialist services with strict criteria, or private clinics with faster access at a price. This guide sets out the eligibility rules, costs and waiting times so you can weigh up which route suits your circumstances.